LIfT BioSciences to present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer
London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data demonstrating the potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) to restore innate immune competence and remodel the tumour microenvironment (TME) in support of anti-tumor immunity, will be presented in a poster at the 40th Society for Immunotherapy of Cancer bein
Nov 6
LIfT BioSciences announces grant of €12 million from Ireland’sDisruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy
Galway, London, 29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Jul 29
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Jun 25
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Jun 4
Our Chairman Tony de Fougerolles discusses innate immune rejuvenation
Chairman of LIfT BioSciences, to explore the concept of innate immune rejuvenation – a central pillar of our approach to overcoming...
May 28
